Nuwellis, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the SEC. The report provides an overview of the company's business, including its focus on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy for patients suffering from fluid overload. The company is also conducting clinical trials and expanding its commercialization efforts in the pediatric market. The filing also mentions the company's efforts to regain compliance with the Minimum Bid Price Requirement for continued listing on the Nasdaq Stock Market.